In This Article:
Over the last 7 days, the Indian market has dropped 1.2%, yet it remains up by an impressive 38% over the past year with earnings forecasted to grow by 17% annually. In this dynamic environment, identifying stocks with strong growth potential and solid fundamentals can be crucial for investors looking to capitalize on emerging opportunities.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Bengal & Assam | 4.48% | 1.53% | 51.11% | ★★★★★★ |
| Wealth First Portfolio Managers | NA | -47.95% | 40.47% | ★★★★★★ |
| Force Motors | 23.24% | 21.52% | 44.24% | ★★★★★☆ |
| Indo Amines | 82.32% | 17.15% | 19.98% | ★★★★★☆ |
| Master Trust | 37.05% | 27.64% | 41.99% | ★★★★★☆ |
| Kaycee Industries | 17.35% | 19.50% | 34.62% | ★★★★★☆ |
| Lotus Chocolate | 13.51% | 28.07% | -10.66% | ★★★★★☆ |
| KP Green Engineering | 13.73% | 47.60% | 61.28% | ★★★★★☆ |
| Magadh Sugar & Energy | 85.44% | 6.65% | 13.60% | ★★★★☆☆ |
| Vasa Denticity | 0.11% | 38.37% | 48.77% | ★★★★☆☆ |
Let's uncover some gems from our specialized screener.
D. P. Abhushan
Simply Wall St Value Rating: ★★★★☆☆
Overview: D. P. Abhushan Limited engages in the manufacturing, sale, and trading of gold, diamond, platinum, silver, and other precious metals and ornaments in India with a market cap of ₹36.93 billion.
Operations: The company generates revenue primarily from the Gems & Jewellery segment, amounting to ₹23.74 billion.
D. P. Abhushan, a notable player in the retail jewellery sector, reported impressive earnings growth of 48.5% over the past year, outpacing the industry average of 23%. The company's debt to equity ratio has significantly improved from 187% to 73.3% over five years, although its net debt to equity remains high at 61%. Recent financials show net income for Q1 2024 at INR 250.77 million, up from INR 156.23 million last year, with basic EPS rising to INR 11.27 from INR 7.02.
-
Navigate through the intricacies of D. P. Abhushan with our comprehensive health report here.
-
Gain insights into D. P. Abhushan's historical performance by reviewing our past performance report.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research, manufacturing, marketing, and sale of pharmaceutical formulations across various international markets including the United States, North America, Europe, the United Kingdom, Australia, and New Zealand; it has a market cap of ₹117.08 billion.
Operations: Marksans Pharma generates revenue primarily from its pharmaceutical segment, amounting to ₹22.68 billion. The company's market cap stands at ₹117.08 billion.